I'll research CME Group before writing the preview. Let me start by gathering recent filings, transcripts, and news.I have the recent Q1 2026 results. Let me read the latest earnings release and call, plus get volume data and monthly volume news.I have strong Q1 detail. Now let me get recent volume trends, stock price performance, and broader recent news for Q2 2026 context.Important development — a CEO transition. Let me read that and get recent monthly volume data and news.Let me get Q2 monthly volume data and analyst expectations via web search.Q2 ADV data is available. Let me read the full June/Q2 volume press release and get consensus estimates and RPC details.Let me pull Q2 2025 actuals for the year-over-year comparison base.I now have a complete picture. Let me write the preview.

CME Group (CME) — Q2 2026 Earnings Preview

Report expected before market open, Wednesday, July 22, 2026 (2026Q2 Earnings Call)

The Setup: A "Beat-Proof" Volume Quarter Into a De-Rated Stock

The unusual thing about this print is that the single most important revenue driver — trading volume — is already known. CME publishes monthly ADV, so investors head into the quarter with the full picture. The debate is therefore not "did volumes hold up," but rather rate capture, expenses, capital return, and — above all — the competitive and strategic narrative that has cut the stock roughly a quarter from its March peak.

Consensus: ~$2.93 adjusted diluted EPS (Zacks) to ~$3.00, essentially flat-to-down ~1% vs. the $2.96 posted in Q2 2025. This would be a sharp sequential step-down from Q1 2026's record $3.36.
Stock: CME closed $237.42 on July 21, down ~12% YTD (from ~$270) and ~27% off the early-March high near $326. The bulk of the damage came in late May–June, when the shares fell from ~$305 to a ~$218 trough. Peer ICE followed a similar path; NDAQ held up better.

The message: expectations have been reset lower, and the report will be judged largely on forward tone around the perpetual-futures / prediction-market threat and the CEO transition, not the Q2 numbers themselves.

1. Volumes: Already Reported — Solid, But Off the Q1 Peak

CME's own monthly releases give us the quarter:

Metric	Q2 2026	Q2 2025	Q1 2026
Total ADV	~29.8M (2nd-highest Q2 ever)	30.2M (record)	36.2M (record)
YoY	~‑1% to flat	+16%	+22%
Sequential	~‑18%	—	—

Monthly cadence tells the real story: - April: 25.9M — clearly soft (management had already flagged "softer activity so far in April" on the Q1 call). - May: 33.2M — a May record, +15% YoY. - June: 30.6M — a June record, +19% YoY, led by equity index +54% (record 10.1M) and crypto +76%.

By complex for the quarter: interest rates ~14.5M (down from Q1's outsized 18.7M and below Q2'25's 15.5M — the key drag), equity index ~8.6M (up double-digits YoY), with gains in energy, ags, metals and crypto. Watch the interest-rate franchise commentary: Q1 benefited from an all-time high in Treasury open interest and rate-repricing volatility; the Q2 IR moderation is the main reason total ADV slipped YoY.

Bottom line: volume is fine but no longer spectacular. The Q1 blowout won't repeat, so the sequential earnings decline is mechanical, not a red flag.

2. Rate Per Contract (RPC): The Real Swing Factor

With volumes known, RPC is where the revenue surprise lives. Q1 RPC fell to $0.652 (from $0.686 in Q1'25 and $0.690 in Q2'25) — driven by four factors management laid out: (1) volume tiering on record volume, (2) mix shift toward lower-priced crude, (3) explosive micro growth (~315k micro energy/day at ~$0.52), and (4) more member trading.

Going into Q2: - Lower total volume than Q1 should relieve some tiering pressure, a modest RPC tailwind. - But the equity-index and crypto surge in June, plus continued micro/retail penetration, can pull the blended rate the other way. - Energy RPC (which dropped to $1.084 in Q1 from $1.222) and the crude/nat-gas mix are worth watching.

A blended RPC that stabilizes near ~$0.66–$0.67 would support the revenue line; a further drift lower would pressure it even with decent volumes.

3. The Two Non-Transaction Engines to Watch

Market data: Q1 hit a record $224M, +15% YoY — the 32nd consecutive quarter of YoY growth. Management attributes momentum to a surge in simulated-trading (sim) environments feeding new retail traders, data-licensing policy changes (end-of-day category), and steady professional subscriber growth (~+2.4% YoY). This is the "quality" revenue the market pays up for — any deceleration would be notable.

Investment income on collateral: In Q1, average cash collateral was ~$149B at ~33 bps, plus ~$171B non-cash at ~10 bps; both balances ticked up in April ($153B / $174B). This float income is meaningful and rate-sensitive — note the backdrop of a newly Warsh-led Fed and the trajectory of short rates.

4. The Overhang: Perpetual Futures, Kalshi & the CFTC Lawsuit

This is the crux of the stock's de-rating and likely the most-asked topic on the call.

The CFTC approved Kalshi to offer bitcoin (then broader crypto) perpetual futures in late May — the first US perpetuals — and CME filed suit against the CFTC on June 17, arguing perpetuals are legally swaps under Dodd-Frank, not futures. Duffy said he'd been working the plan with the board for eight months and stressed CME holds exclusive index licenses with every benchmark provider.
Separately, the CFTC stayed CME's own attempt to self-certify 24/7 crude oil futures in early July, pending review — a reminder the regulatory pendulum cuts both ways.
On the Q1 call, Duffy was emphatic that perpetuals are "against the law" in the US and that notional "explosion" on venues like Hyperliquid is not comparable to CME contract volumes, and carries auto-liquidation/socialized-loss risk unsuitable for institutional hedgers.

What to listen for: any update on the litigation timeline, competitive volume leakage (or lack thereof), and whether CME defends share in crypto/benchmark products. Management's framing here will move the stock more than the EPS.

5. CEO Transition — First Change at the Top in a Generation

On June 17, CME named CFO/President Lynne Fitzpatrick as CEO effective March 1, 2027, with Terry Duffy moving to Executive Chairman after more than two decades leading the company. Fitzpatrick, a CME veteran since 2006, has run finance, capital allocation and IR. Shares fell ~4% on the news; sell-side reaction (e.g., Piper Sandler) was broadly confident in continuity. Because Fitzpatrick already delivers the financial results on the call, expect a smooth Q&A — but watch for strategy/priority signaling as she steps toward the top job.

6. Growth Initiatives — Progress Checks

Several 2026 launches should get updates: - Prediction markets / FanDuel JV: >220M contracts since December launch; >150k new accounts; notably, market-based contracts (equity/crypto/energy/metals) exceeded 30% of volume post-March marketing — validating the "distribution, not sports" thesis. Watch FCM pipeline and the FanDuel-own-FCM question (management says contractual restrictions protect the JV). - New products: 90%/50% lean beef trim futures (launched July 20), a proposed AI-compute futures contract with Silicon Data, four new E-mini contracts, a 10-barrel WTI micro contract (Aug 30), and 24/7 gold (July 26). - Micro equity index options moving to financial settlement to better serve retail. - Google Cloud / Dallas facility: on track to open this summer as a testing ground, with two ag products migrating to the cloud by year-end; cash tokenization (BMO pilot) and a potential CME stablecoin targeted to advance in 2026. - Cross-margining: FICC/CME client cross-margining went live April 30 (up to ~80% savings potential); house program already saves ~$1B+/day. Record $85B/day in average margin savings was a Q1 highlight.

7. Expenses, Capital Return & Model Notes

Expense guide: Management affirmed ~$1.695B adjusted 2026 opex at Q1. Q1 adjusted expenses ex-license grew ~7% YoY on variable comp/tech tied to record activity; expect occupancy (Dallas) and cloud/tech costs to build through the year. Any guide change is a key modeling input.
Margins: Q1 adjusted operating margin hit a record 72.8%; a lower-volume Q2 likely gives some back.
Capital return: CME pays a large variable annual dividend plus buybacks; it is deploying ~$1.55B of OSTTRA sale proceeds into repurchases (~$758M remaining at end-Q1 after $536M bought in Q1). Duffy left the door open to M&A if the right opportunity arises.
Share count: The Google preferred shares converted to common in Q1, so the preferred/common EPS distinction disappears going forward.

What Would Make the Print a Beat vs. a Miss

Bullish signals	Bearish signals
Blended RPC stabilizes/ticks up as tiering eases	RPC drifts lower on micro/mix shift
Market data sustains ~mid-teens growth	Data growth decelerates
Constructive tone / early wins vs. perpetuals	Signs of share/volume leakage to Kalshi/DeFi venues
Expense guide held; buyback pace strong	Opex creep from cloud/Dallas above guide
July MTD volume commentary strong	Soft July / IR volume fade continues

Net: The numbers should land close to a modest YoY EPS decline (~$2.9–$3.0) on flat-ish volume — largely in the price. The stock's next move hinges less on Q2 results and more on management's defense of the moat against perpetual/prediction-market competition, the RPC trajectory, and continuity signals from the incoming-CEO/CFO Fitzpatrick.

Sources: CME Q1 2026 earnings release & call transcript; Q2 2025 earnings release; CME monthly ADV releases for April/May/June 2026; Reuters/CNBC/FT coverage of the CEO transition and CFTC/Kalshi litigation; Zacks/consensus estimates; daily price data through July 21, 2026. Figures are approximate where drawn from preliminary monthly disclosures and consensus.